Clinical Trial Search

Primary: Long Term Immunogenicity of IC51 Vaccine 24 Months After the Primary Vaccination — 56; 7; 5 percentage of participants

Primary: Percentage of Participants Meeting Serum Total Testosterone Average Concentration (Cavg) Criteria at Day 90 — 77.5 percentage of participants

Primary: Juvenile Arthritis Quality of Life Questionnaire (JAQQ) — 2.35; 2.74; 1.95; 2.27 units on a scale

Primary: Percentage of Participants With Reduction in Grade 3/4 Neutropenia — 40; 13 percentage of participants

Primary: Safety and Tolerability of a Single Ascending Doses of Intravenous N6022 in Healthy Volunteers — 1; 4; 1; 0 Adverse Events

Primary: Wolf Motor Function Test (Time) — 10.21; 29.69; 19.09; 26.05 units on a scale — p=<0.05

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 15; 3; 10; 4 participants

Primary: Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD. — 1; 0; 0; 0 number of DLT

Primary: Change in Body Weight. — 1.2; 1.2; 3.7 kg

Primary: Number of Patients With Complete Response During Chemotherapy Course 1 — 17; 26 participants — p=0.04

Primary: In Vivo Linear Kinematics for Fixed-bearing and Rotating Platform (RP) TKA System During 4 Weight-bearing Activities. — -3.51; -2.52; -1.68; -1.40 mm

Primary: Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS) — 259.0; 39.4 scores on a scale

Primary: Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS) — 268.8; 230.9; 54.8 scores on a scale

Primary: Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analogue Scale (VAS) — 720.5; 239.9; 614.4; 450.8 scores on a scale

Primary: Time to Vaginal Delivery During the First Hospital Admission — 1292.00; 1968.50 minutes — p=<0.001